Get the Stockscreener App
7.07
6.16%
0.41
Pre-market:
7.01
-0.06
-0.85%
Regenxbio Inc stock is traded at $7.07, with a volume of 1.64M.
It is up +6.16% in the last 24 hours and up +23.60% over the past month.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
See More
Previous Close:
$6.66
Open:
$6.79
24h Volume:
1.64M
Relative Volume:
1.36
Market Cap:
$365.50M
Revenue:
$170.44M
Net Income/Loss:
$-193.88M
P/E Ratio:
-1.8833
EPS:
-3.7541
Net Cash Flow:
$-126.38M
1W Performance:
+15.33%
1M Performance:
+23.60%
6M Performance:
-48.88%
1Y Performance:
-23.73%
1-Day Range:
$6.75
$7.11
1-Week Range:
$5.88
$7.11
52-Week Range:
$5.455
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.07 | 365.50M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy - Eastern Progress
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Eastern Progress
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $26 - Moomoo
H.C. Wainwright lowers Regenxbio stock price target on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright lowers Regenxbio stock price target on trial data - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM) - The Globe and Mail
Understanding Momentum Shifts in (RGNX) - Stock Traders Daily
JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc. - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
RGNX Maintains Rating by HC Wainwright & Co. -- Price Target Low - GuruFocus
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
RGNX Maintains Rating by HC Wainwright & Co. -- Price Target Lowered to $26 - GuruFocus
Regenxbio slides after late-stage trial data for Duchenne therapy - MSN
JPMorgan affiliates report 4.4% stake in REGENXBIO (RGNX) in 13G/A - Stock Titan
REGENXBIO (RGNX) offers exchange of 2.9M eligible options for replacements - Stock Titan
REGENXBIO (NASDAQ: RGNX) investors back board, reject executive option swap - Stock Titan
REGENXBIO (RGNX) awards director Daniel Tasse RSUs and options - Stock Titan
REGENXBIO (RGNX) director receives new RSU and stock option awards - Stock Titan
[Form 4] REGENXBIO Inc. Insider Trading Activity - Stock Titan
REGENXBIO (RGNX) director Kenneth Mills granted RSUs and 46,600 stock options - Stock Titan
REGENXBIO (RGNX) director awarded 9,807 RSUs and 46,600 stock options - Stock Titan
Director at REGENXBIO (RGNX) receives RSU and option grants - Stock Titan
REGENXBIO Inc. (RGNX) director receives new RSU and stock option grants - Stock Titan
Equity grants to REGENXBIO (NASDAQ: RGNX) director Jean Bennett - Stock Titan
How The REGENXBIO (RGNX) Investment Story Is Evolving Without New Analyst Commentary - Yahoo Finance
RGNX Should I Buy - Intellectia AI
RGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial success - MSN
Regenxbio files $300M mixed shelf offering - MSN
REGENXBIO to push for accelerated approval of DMD gene therapy - MSN
Stifel reiterates Buy rating on Regenxbio stock ahead of trial data - Investing.com UK
Stifel reiterates Buy rating on Regenxbio stock ahead of trial data By Investing.com - Investing.com South Africa
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Avoiding Lag: Real-Time Signals in (RGNX) Movement - Stock Traders Daily
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
Morgan Stanley Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $6.25 - Moomoo
RGNX: Rolling BLA for Duchenne gene therapy set for Q3 2024, with robust data and regulatory momentum - TradingView
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway - Insider Monkey
RegenXbio’s RGX-202 Pivotal Win Lifts Outlook - TipRanks
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):